|
octa |
18 |
|
prevalence |
13 |
|
cataract |
11 |
|
chinese |
11 |
|
epidemiology |
11 |
|
exophthalmometry values |
11 |
|
hertel's |
11 |
|
hong kong |
11 |
|
macular vascular density |
11 |
|
macular vessel density |
11 |
|
optical coherence tomography angiography |
11 |
|
proptosis |
11 |
|
visual impairment |
11 |
|
eye diseases |
9 |
|
asians |
8 |
|
ocular surface disease |
8 |
|
severe cutaneous adverse reactions |
8 |
|
stevens–johnson syndrome |
8 |
|
toxic epidermal necrolysis |
8 |
|
covid-19 |
7 |
|
glaucoma |
7 |
|
macular microcirculation |
7 |
|
neuroprotection |
7 |
|
obesity |
7 |
|
vessel density |
7 |
|
acute ocular hypertensive injury |
6 |
|
amphiphilic |
6 |
|
anti-inflammatory |
6 |
|
anti-vegf |
6 |
|
bevacizumab |
6 |
|
emulsification |
6 |
|
eye‐on‐a‐chip |
6 |
|
pandemic |
6 |
|
pterygium |
6 |
|
ranibizumab |
6 |
|
silicone oil |
6 |
|
transcorneal electrical stimulation |
6 |
|
3d culturing |
5 |
|
aerosolization |
5 |
|
aerosols |
5 |
|
age-related macular degeneration |
5 |
|
autoimmune encephalitis |
5 |
|
awareness |
5 |
|
cardiac dysfunction |
5 |
|
cardiac function reserve |
5 |
|
chemicals and cas registry numbers |
5 |
|
covid |
5 |
|
diabetic cardiomyopathy |
5 |
|
diabetic retinopathy |
5 |
|
droplets |
5 |
|
exercise echocardiography |
5 |
|
fibroblasts |
5 |
|
high‐molecular‐weight additive |
5 |
|
knowledge |
5 |
|
limbic encephalitis |
5 |
|
myofibroblasts |
5 |
|
optic neuritis |
5 |
|
paraneoplastic syndrome |
5 |
|
phacoemulsification |
5 |
|
risk factors |
5 |
|
stevens-johnson syndrome |
5 |
|
stromal fibrosis |
5 |
|
survey |
5 |
|
systematic review |
5 |
|
transforming growth factor-beta 1 |
5 |
|
corneal scarring |
4 |
|
direct ophthalmoscopy |
4 |
|
electrical phosphene threshold |
4 |
|
electrical stimulation |
4 |
|
fibroblast |
4 |
|
human keratocytes |
4 |
|
lycium barbarum polysaccharides |
4 |
|
medical education |
4 |
|
retinal degeneration |
4 |
|
tgfβ1 |
4 |
|
visual function |
4 |
|
age |
3 |
|
ahmed glaucoma valve |
3 |
|
animal models |
3 |
|
atropine |
3 |
|
autoimmune diseases |
3 |
|
autoimmune disorders |
3 |
|
autophagy inhibitors |
3 |
|
cancer treatment |
3 |
|
cell therapy |
3 |
|
childhood myopia |
3 |
|
chinese population |
3 |
|
ciliochoroidal detachment |
3 |
|
clinical practice |
3 |
|
cornea |
3 |
|
cornea stromal scarring |
3 |
|
coronavirus |
3 |
|
dark agouti rats |
3 |
|
diabetes |
3 |
|
diabetes mellitus |
3 |
|
diagnosis |
3 |
|
diet supplementation |
3 |
|
diurnal intraocular pressure fluctuation |
3 |
|
dry eye syndrome |
3 |
|
east respiratory |
3 |
|
electrical stimulation therapy |
3 |
|
electroretinographic responses |
3 |
|
epithelial wound healing |
3 |
|
epithelium |
3 |
|
experimental therapy |
3 |
|
eye |
3 |
|
eye hemorrhage |
3 |
|
gene mutation |
3 |
|
glucose control |
3 |
|
graves’ disease |
3 |
|
herpes simplex keratitis |
3 |
|
hypoxia |
3 |
|
immune checkpoint inhibitors |
3 |
|
immune homeostasis |
3 |
|
immune-related adverse events |
3 |
|
immunity |
3 |
|
infectious keratitis |
3 |
|
inflammatory eye disease |
3 |
|
intestinal microbiota |
3 |
|
lamp1 |
3 |
|
lc3 |
3 |
|
machine learning |
3 |
|
macroautophagy |
3 |
|
management |
3 |
|
meta-analysis |
3 |
|
microbead occlusion |
3 |
|
middle east |
3 |
|
minimization |
3 |
|
myopia progression control |
3 |
|
ocular disease |
3 |
|
ophthalmic considerations |
3 |
|
ophthalmic diseases |
3 |
|
ophthalmic specialty clinics |
3 |
|
photoreceptor |
3 |
|
prevention |
3 |
|
public health care system |
3 |
|
rat |
3 |
|
rcts |
3 |
|
retinal diseases |
3 |
|
retinal ganglion cell |
3 |
|
success rate |
3 |
|
systemic treatment |
3 |
|
therapy |
3 |
|
thyroid eye disease |
3 |
|
topical treatment |
3 |
|
triage |
3 |
|
vision |
3 |
|
compliance |
2 |
|
digital literacy |
2 |
|
dry eye disease |
2 |
|
dry eye treatment |
2 |
|
e-learning |
2 |
|
evidence-based |
2 |
|
eye drop |
2 |
|
eyelid warming |
2 |
|
higher order aberrations |
2 |
|
intense pulsed-light therapy |
2 |
|
medical sciences |
2 |
|
meibomian gland dysfunction |
2 |
|
problem-based learning |
2 |
|
quality of life |
2 |
|
surgery |
2 |
|
tear film |
2 |
|
technology |
2 |
|
thermal pulsation |
2 |
|
treatment |
2 |
|
warm compress |
2 |
|
access |
1 |
|
angiography |
1 |
|
antibiotic |
1 |
|
astigmatism |
1 |
|
breast cancer |
1 |
|
chloramphenicol |
1 |
|
coagulation abnormalities |
1 |
|
corneal sensitivity |
1 |
|
densiometry |
1 |
|
diagnostic tests/investigation |
1 |
|
dry eye |
1 |
|
dry eyes |
1 |
|
endoscopic retrograde cholangiopancreaticogram |
1 |
|
equity |
1 |
|
financial protection |
1 |
|
gene-based therapy |
1 |
|
glaucoma neuroprotection |
1 |
|
imaging |
1 |
|
inflammation |
1 |
|
keratoconjunctivitis sicca |
1 |
|
laser refractive surgery |
1 |
|
lasik |
1 |
|
myopia |
1 |
|
ocular surface |
1 |
|
ocular surface equilibrium |
1 |
|
optic nerve injury |
1 |
|
over-the-counter drug |
1 |
|
randomized controlled trials |
1 |
|
refraction |
1 |
|
refractive error |
1 |
|
refractive surgery |
1 |
|
sex hormones |
1 |
|
sjögren's syndrome |
1 |
|
smile |
1 |
|
spectacles |
1 |
|
spontaneous retrobulbar hemorrhage |
1 |
|
tear film biomarkers |
1 |
|
tears |
1 |
|
tomography |
1 |
|
topography |
1 |
